Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Avolon Holdings Ltd (AVOL) Sold To Chinese Firm Following Seven Week Courtship

Page 1 of 2

The $2.36 billion aircraft leasing and lease management service provider, Avolon Holdings Ltd (NYSE:AVOL) announced today that it has reached an agreement with China-based Bohai Leasing in a deal that puts the enterprise value of Avolon Holdings Ltd (NYSE:AVOL) at $7.6 billion. In addition to the $31 per share price tag, which represents a 31% premium to the stock’s price on July 13, when news of Bohai’s intentions to acquire a 20% stake in the company surfaced on the market. The deal also includes the assumption of debt. According to Avolon’s announcement in August, the sale price was being discussed at the $32 per share level, which was ultimately revised down due to the current market volatility. However, Bohai increased its deposit by $100 million to $350 million in order to provide greater certainty to the transaction and express its seriousness. This amount will be paid to Avolon Holdings Ltd (NYSE:AVOL) in case the transaction doesn’t finalize. As far as shareholder approval is concerned, major stockholders of Avolon including CVC Capital, Cinven, Oak Hill Capital and GIC have agreed to vote in favor of the deal as has HNA Group, the largest stockholder of Bohai.


Hedge funds had mixed sentiment towards Avolon Holdings Ltd (NYSE:AVOL) during the second trimester. Even though the total number of funds with investments in the company rose to 15 at the end of June compared to 12 at the end of March, the aggregate investment slid to $90.65 million from $130.44 million. This decline came despite a 6.22% gain in Avolon’s stock price during the second trimester, so a lot of money was being yanked out of the stock by hedgies.

Most investors can’t outperform the stock market by individually picking stocks because stock returns aren’t evenly distributed. A randomly picked stock has only a 35% to 45% chance (depending on the investment horizon) to outperform the market. There are a few exceptions, one of which is when it comes to purchases made by corporate insiders. Academic research has shown that certain insider purchases historically outperformed the market by an average of seven percentage points per year. This effect is more pronounced in small-cap stocks. Another exception is the small-cap stock picks of hedge funds. Our research has shown that the 15 most popular small-cap stocks among hedge funds outperformed the market by nearly a percentage point per month between 1999 and 2012. We have been forward testing the performance of these stock picks since the end of August 2012 and they have returned more than 118% over the ensuing 36 months, outperforming the S&P 500 Index by nearly 60 percentage points (read the details here). The trick is focusing only on the best small-cap stock picks of funds, not their large-cap stock picks which are extensively covered by analysts and followed by almost everybody.

Keeping in mind the value of the rigorous research that hedge funds carry out before they take a position, let’s see which money managers have been betting in favor of Avolon Holdings Ltd (NYSE:AVOL). On the top of our list of Avolon Holdings Ltd (NYSE:AVOL)’s stockholders is Israel Englander‘s Millennium Management, which has held a stake in the company since the fourth quarter of last year and increased its holding by 9% during the second quarter to 1.41 million shares valued at $32.49 million. Next in line is Clint Carlson‘s Carlson Capital, which added the stock to its portfolio during the same quarter as Millennium, and during the June trimester, boosted the holding by 8% to about 572,600 shares valued at $13.15 million. David E. Shaw‘s D E Shaw has also been bullish on the company, increasing its holding by about 120% to more than 416,900 shares valued at $9.57 million.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!